Atopix Therapeutics
Pioneering new frontiers in allergy treatment with breakthrough CRTH2 antagonists.
Pioneering new frontiers in allergy treatment with breakthrough CRTH2 antagonists.
Atopix Therapeutics is a UK-based biopharmaceutical company founded in 2012, with a focus on revolutionizing allergy treatment through the development of CRTH2 antagonists. The company's lead candidate, currently in a Phase 2 clinical trial for atopic dermatitis, has garnered significant attention and secured a Venture Round investment from SV Health Investors in November 21, 2016. Atopix Therapeutics' pioneering approach and strategic partnerships position it as a key player in the Biotechnology and Life Sciences industries, demonstrating promising potential for the future of allergy treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 |
|
21 Nov 2016 |
| Debt Financing | £3.25M | 1 | Silicon Valley Bank | 03 Jul 2015 |
| Series A | $3.70M | 5 |
|
08 Oct 2014 |
| Grant | $1.70M | 1 | Biomedical Catalyst Fund | 30 May 2013 |
No recent news or press coverage available for Atopix Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
